International Defense Security & Technology Your trusted Source for News, Research and Analysis
Related Articles
Can We Produce RNA Medicines Without Harming the Planet?
As RNA therapies reshape modern medicine, innovators are racing to build cleaner, scalable, and more sustainable ways to synthesize the molecule that could cure everything from cancer to rare genetic diseases.
The COVID-19 pandemic thrust RNA into the spotlight, showcasing its potential to revolutionize medicine through vaccines developed in record time. Yet, long before the pandemic, RNA therapies were already making waves in treating rare genetic disorders like Duchenne Muscular Dystrophy and amyloidosis. These therapies offer unparalleled precision, capable of targeting specific genetic components and even guiding CRISPR gene-editing tools to their destinations. However, as demand for RNA-based treatments surges, a critical bottleneck threatens progress: the outdated methods of RNA synthesis.
The RNA Revolution: Beyond Vaccines
RNA oligonucleotides—short synthetic strands of RNA—are spearheading a medical revolution, offering hope for diseases once considered untreatable. Leading this charge are therapies like Exondys 51, an FDA-approved treatment for Duchenne Muscular Dystrophy that bypasses defective gene segments to restore protein production, and Patisiran, a siRNA drug that silences disease-causing genes in hereditary amyloidosis. Unlike traditional small-molecule drugs, RNA therapies boast unmatched adaptability: they can be rapidly redesigned to target emerging pathogens or genetic mutations, making them indispensable in combating evolving diseases. Their versatility extends to collaboration with CRISPR systems, as seen in experimental treatments for sickle cell anemia, where RNA guides gene-editing tools to precise genomic targets.
The Manufacturing Bottleneck: Stuck in the 1980s
Despite their promise, RNA therapies face a critical hurdle rooted in decades-old manufacturing methods. Chemical synthesis, the industry standard since the 1980s, generates staggering environmental costs—producing just 1 kilogram of RNA yields 3 tons of hazardous waste, including carcinogenic solvents like acetonitrile. This process also struggles to incorporate modified nucleotides essential for modern therapies, such as pseudouridine in mRNA vaccines, stifling innovation. Compounding these issues, reliance on manual processes and specialized equipment limits global RNA production to ~1 ton annually, far below the projected 10+ tons needed by 2030. Stringent environmental regulations exacerbate the crisis, forcing manufacturers to allocate 30–50% of their capacity to waste management rather than scaling output. These constraints threaten to delay life-saving therapies unless urgent modernization occurs.
By addressing these challenges, the industry can unlock RNA’s full potential, transforming medicine while prioritizing sustainability and scalability.
Environmental and Economic Fallout
The ecological toll of RNA production is staggering. In 2022, a single U.S. facility reported releasing 12,000 gallons of solvent waste monthly, contaminating local water supplies. Meanwhile, reliance on rare phosphoramidite building blocks drives costs to 500–1,000 per gram, pricing out lower-income patients.
Innovative Solutions: Modernizing RNA Synthesis
To overcome these challenges, scientists and startups are pioneering cutting-edge approaches that reimagine RNA production. Leading the charge is enzymatic synthesis, exemplified by companies like Wave Life Sciences, which employs RNA polymerase enzymes to assemble strands with 90% less waste compared to traditional methods. This technique not only minimizes environmental harm but also supports the integration of exotic nucleotides, enabling therapies for complex targets such as cancer neoantigens.
Meanwhile, continuous flow systems are revolutionizing efficiency. Platforms like Nuclera’s automate synthesis, slashing production time from days to mere hours while reducing costs by 70% and eliminating human error. These systems streamline workflows, allowing rapid scaling to meet surging demand.
Sustainability is also taking center stage through green chemistry. Startups such as ReCode Therapeutics are replacing toxic solvents with water-based alternatives and recyclable reagents, targeting zero-waste production by 2025. This shift not only aligns with global environmental goals but also circumvents regulatory bottlenecks tied to hazardous waste.
Complementing these advances, machine learning is accelerating drug design. Deep Genomics leverages AI to predict optimal RNA sequences, compressing preclinical development from years to months. By simulating molecular interactions and optimizing stability, these tools unlock novel therapies for genetic disorders and infectious diseases alike.
Together, these innovations are dismantling decades-old barriers, paving the way for scalable, sustainable, and precision-driven RNA therapeutics that promise to redefine modern medicine.
Breakthrough Innovation: Enzymatic RNA Synthesis at Harvard’s Wyss Institute
A major leap toward this future has just been achieved. A team of scientists at the Wyss Institute at Harvard University and Harvard Medical School (HMS) has developed a revolutionary enzymatic RNA synthesis process that could dramatically transform the field. Described in a paper published in Nature Biotechnology, the method uses water and enzymes instead of toxic solvents and explosive catalysts, while maintaining purities and efficiencies comparable to existing chemical synthesis technologies.
This novel platform not only supports the incorporation of all current RNA drug modifications, but it also opens the door to novel RNA chemistries that could power entirely new classes of RNA therapeutics. Co-first author Jonathan Rittichier, Ph.D., a former postdoctoral fellow at the Wyss and HMS, emphasized the urgency:
“As demand for RNA drugs continues to grow… we will exceed the current global supply of acetonitrile, the organic solvent used in chemical RNA synthesis methods.”
To commercialize this innovation, Rittichier and his colleagues—including Daniel Wiegand, M.S.Ch.E., and renowned geneticist George Church, Ph.D.—founded EnPlusOne Biosciences. Their mission: to enable a bioinspired, renewable RNA synthesis platform at global scale.
How the New Process Works
The team began by adapting an RNA-linking enzyme from Schizosaccharomyces pombe yeast. They engineered it for higher efficiency and the ability to incorporate non-standard, chemically modified nucleotides, which are essential for creating therapeutic RNA with enhanced stability or functionality.
Unlike traditional synthesis, which uses chemical “protecting groups” to shield nucleotides from harsh reactions, this enzymatic method avoids such toxic intermediates entirely. To ensure precise RNA sequence assembly, they also introduced a “blocker” molecule—a clever innovation that pauses the enzyme after each nucleotide addition. This allowed them to build RNA one base at a time with remarkable 95% efficiency, matching or exceeding the precision of chemical synthesis.
In tests, the process successfully created 23-nucleotide-long RNA strands, which are comparable in size to leading RNA-based drugs. It also integrated multiple types of modified nucleotides, paving the way for more diverse and potent therapeutic designs.
From Molecules to Medicines
This groundbreaking work was further advanced through a Validation Project at the Wyss Institute and later became the first project supported by the Laboratory for Bioengineering Research and Innovation in partnership with Northpond Labs. EnPlusOne Biosciences, launched in 2022, is now building on this success to produce small interfering RNAs (siRNAs) and high-quality guide RNAs for CRISPR/Cas gene editing, among other applications.
“This platform can help unlock the immense potential of RNA therapeutics in a sustainable way,” said co-corresponding author George Church. Wyss Institute Founding Director Don Ingber, M.D., Ph.D., echoed the sentiment:
“EnPlusOne’s elegant bioinspired enzyme synthesis alternative offers a way to overcome all these limitations… and could help the RNA therapeutics industry to explode.”
The Road Ahead: Scaling Sustainably
The global RNA market, valued at 5 billion in 2023, is projected to reach 25 billion by 2030, driven by breakthroughs in vaccines, gene therapies, and personalized medicine. Achieving this exponential growth demands a coordinated, multi-pronged strategy that prioritizes sustainability, innovation, and inclusivity.
Central to this effort is collaboration across sectors. Partnerships like Moderna and Cytiva’s $500 million joint venture are pioneering modular, eco-friendly production hubs designed to decentralize RNA manufacturing. These facilities leverage renewable energy and closed-loop systems to minimize waste, setting a blueprint for scalable infrastructure. Similarly, alliances between academia and industry—such as BioNTech’s collaboration with the Uganda Cancer Institute to develop mRNA therapies for African populations—demonstrate how shared expertise can democratize access to cutting-edge treatments.
Equally critical is regulatory agility. The FDA’s 2023 Green Manufacturing Initiative exemplifies this shift, fast-tracking approvals for sustainable synthesis methods like enzymatic RNA production. Europe’s REACH regulations are being updated to incentivize solvent-free processes, while Singapore’s Health Sciences Authority has launched a sandbox program to accelerate RNA drug trials. Such policies not only reduce time-to-market but also align with global climate goals, ensuring that biomanufacturing evolves responsibly.
Public investment serves as the bedrock of innovation. The EU’s Horizon Europe program has allocated €1 billion to advance nucleic acid therapeutics, funding projects ranging from CRISPR-guided RNA therapies to AI-driven drug design. In the U.S., the Advanced Research Projects Agency for Health (ARPA-H) is channeling $2.5 billion into scalable RNA platforms, targeting rare diseases and pandemic preparedness. Emerging economies like India and Brazil are also prioritizing RNA R&D through national biotech missions, aiming to build domestic capacity and reduce reliance on imports.
To sustain this momentum, the industry must address systemic gaps—such as workforce training and supply chain resilience—while fostering ethical frameworks for equitable access. By uniting innovation with sustainability, the RNA sector can transcend today’s bottlenecks, delivering transformative therapies to millions while safeguarding our planet’s future.
Conclusion: A Greener, Scalable Future for RNA Therapeutics
RNA therapies hold the key to curing genetic diseases, personalized cancer treatments, and pandemic preparedness. Yet, their promise hinges on modernizing synthesis to be scalable, affordable, and environmentally sound. By embracing enzymatic platforms, AI-driven design, and circular manufacturing, the industry can turn today’s challenges into tomorrow’s cures. The question is not if RNA will transform medicine, but how quickly we can reengineer its production to meet the world’s needs.
The future of medicine is written in RNA—let’s ensure it’s sustainable.
